Skip to content

Safety and Effectiveness of the Opira AIOL in Comparison to Commercial IOLs in Patients Undergoing Cataract Surgery

Evaluation of the Visual Performance and Safety of the Investigational Opira AIOL, A Commercial Multifocal IOL, and a Commercial Monofocal IOL

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04756908
Enrollment
200
Registered
2021-02-16
Start date
2020-10-08
Completion date
2024-06-30
Last updated
2023-02-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cataract

Brief summary

This is a clinical trial comparing an investigative accommodative IOL and two commercial IOLs in patients with cataracts undergoing primary cataract surgery.

Detailed description

This is a prospective, multicenter clinical study comparing the safety and performance of the Opira accommodative IOL, a commercial monofocal IOL, and a commercial multifocal IOL. Eligible patients with bilateral cataracts will undergo cataract surgery implanting one of three study lenses, and will be followed postoperatively for 24 months

Interventions

DEVICECataract Surgery

The surgical procedure in which the natural crystalline lens is removed and replaced with a lens implant.

Sponsors

FSV6, Ltd.
Lead SponsorINDUSTRY

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
50 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Male and female subjects aged 50-75 with bilateral cataracts, good potential vision, and clear intraocular media other than lens opacity

Exclusion criteria

* Comorbidities affecting visual acuity, IOP \> 22mmHg, congential cataract

Design outcomes

Primary

MeasureTime frame
Visual Acuity6 Months
Adverse event rates12 Months

Countries

Costa Rica, Mexico

Contacts

Primary ContactPaul Rhee, O.D
prhee@forsightv6.com9492944191

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026